Viking Therapeutics (VKTX) has entered into a common stock purchase agreement with Aspire Capital Fund, LLC under which Aspire will buy up to $12.5 million in stock over the next 30 months at market prices at Viking's discretion. Aspire has made an initial purchase of $500K in shares at $1.50. Net proceeds will be used for general corporate purposes.